Astra, Daiichi's Enhertu shows early promise in HER2 lung cancer

After earning an FDA nod for breast cancer in December four months ahead of schedule, AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody-drug conjugate Enhertu is showing some early promise in a phase 1 trial in other cancer types. The antibody-drug conjugate produced a 55.6% objective response rate in HER2-positive non-small cell lung cancer patients.